Down-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer

Changes in the regulation of endocannabinoid production, together with an altered expression of their receptors are hallmarks of cancer, including colorectal cancer (CRC). Although several studies have been conducted to understand the biological role of the CB1 receptor in cancer, little is known about its involvement in the metastatic process of CRC. The aim of this study was to investigate the possible link between CB1 receptor expression and the presence of metastasis in patients with CRC, investigating the main signaling pathways elicited downstream of CB1 receptor in colon cancer. Fifty-nine consecutive patients, with histologically proven colorectal cancer, were enrolled in the study, of which 30 patients with synchronous metastasis, at first diagnosis and 29 without metastasis. A low expression of CB1 receptor were detected in primary tumor tissue of CRC patients with metastasis and consequently, we observed an alteration of CB1 receptor downstream signaling. These signaling routes were also altered in intestinal normal mucosa, suggesting that, normal mucosa surrounding the tumor provides a realistic picture of the molecules involved in tissue malignant transformation. These observations contribute to the idea that drugs able to induce CB1 receptor expression can be helpful in order to set new anticancer therapeutic strategies.

[1]  C. Karapetis,et al.  First‐line therapy for metastatic colorectal cancer: Current perspectives and future directions , 2019, Asia-Pacific Journal of Clinical Oncology.

[2]  A. Passaniti,et al.  Identification of Cross Talk between FoxM1 and RASSF1A as a Therapeutic Target of Colon Cancer , 2019, Cancers.

[3]  M. Ankem,et al.  Suppression of Notch1 and AKT mediated epithelial to mesenchymal transition by Verrucarin J in metastatic colon cancer , 2018, Cell Death & Disease.

[4]  J. Mrdjanović,et al.  A Review of the Therapeutic Antitumor Potential of Cannabinoids. , 2017, Journal of alternative and complementary medicine.

[5]  G. Giannelli,et al.  Dietary ω-3 Polyunsaturated Fatty Acids Inhibit Tumor Growth in Transgenic ApcMin/+ Mice, Correlating with CB1 Receptor Up-Regulation , 2017, International journal of molecular sciences.

[6]  G. Velasco,et al.  Anticancer mechanisms of cannabinoids. , 2016, Current oncology.

[7]  C. L. Le Maitre,et al.  Expression of Cannabinoid Receptors in Human Osteoarthritic Cartilage: Implications for Future Therapies , 2016, Cannabis and cannabinoid research.

[8]  R. D'Alessandro,et al.  Anti Proliferative and Pro Apoptotic Effects of Flavonoid Quercetin Are Mediated by CB1 Receptor in Human Colon Cancer Cell Lines , 2015, Journal of cellular physiology.

[9]  A. Malfitano,et al.  Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells , 2015, Oncotarget.

[10]  C. Laezza,et al.  The endocannabinoid signaling system in cancer. , 2013, Trends in pharmacological sciences.

[11]  J. M. Park,et al.  Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer , 2012, Oncology letters.

[12]  G. Velasco,et al.  Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy , 2011, Cell Death and Differentiation.

[13]  J. Groopman,et al.  Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy , 2011, Molecular Cancer Therapeutics.

[14]  A. Malfitano,et al.  Update on the endocannabinoid system as an anticancer target , 2011, Expert opinion on therapeutic targets.

[15]  G. Velasco,et al.  Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy , 2011, Cell Death and Differentiation.

[16]  V. Tutino,et al.  Effects of anandamide on polyamine levels and cell growth in human colon cancer cells. , 2010, Anticancer research.

[17]  M. Caraglia,et al.  Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. , 2009, Oncology reports.

[18]  C. Bass,et al.  Signal transduction via cannabinoid receptors. , 2009, CNS & neurological disorders drug targets.

[19]  I. Díaz-Laviada,et al.  Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB2 , 2009, British Journal of Cancer.

[20]  P. Pandolfi,et al.  Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. , 2009, The Journal of clinical investigation.

[21]  R. Pertwee,et al.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines , 2009, British journal of pharmacology.

[22]  P. Stattin,et al.  A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. , 2009, European journal of cancer.

[23]  G. Alpini,et al.  Changes in the endocannabinoid system may give insight into new and effective treatments for cancer. , 2009, Vitamins and hormones.

[24]  S. Dey,et al.  Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. , 2008, Cancer research.

[25]  H. Friess,et al.  Cannabinoids in pancreatic cancer: Correlation with survival and pain , 2008, International journal of cancer.

[26]  O. Oliviero,et al.  Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor‐suppressor efficacy , 2007, Journal of cellular physiology.

[27]  X. Miao,et al.  Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. , 2006, Cancer genetics and cytogenetics.

[28]  M. Vitale,et al.  Anandamide inhibits adhesion and migration of breast cancer cells. , 2006, Experimental cell research.

[29]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[30]  B. Cravatt,et al.  The endogenous cannabinoid system protects against colonic inflammation. , 2004, The Journal of clinical investigation.

[31]  F. Entschladen,et al.  Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes , 2004, Cancer Immunology, Immunotherapy.

[32]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[33]  M. Maccarrone,et al.  The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis , 2003, Cell Death and Differentiation.